Hemostemix Inc - Asset Resilience Ratio

Latest as of September 2025: 10.87%

Hemostemix Inc (HEM) has an Asset Resilience Ratio of 10.87% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Hemostemix Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CA$145.58K
≈ $105.31K USD Cash + Short-term Investments

Total Assets

CA$1.34 Million
≈ $968.53K USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2018)

This chart shows how Hemostemix Inc's Asset Resilience Ratio has changed over time. See Hemostemix Inc balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Hemostemix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hemostemix Inc market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CA$0.00 0%
Short-term Investments CA$145.58K 10.87%
Total Liquid Assets CA$145.58K 10.87%

Asset Resilience Insights

  • Moderate Liquidity: Hemostemix Inc has 10.87% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Hemostemix Inc Industry Peers by Asset Resilience Ratio

Compare Hemostemix Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Spyre Therapeutics Inc.
NASDAQ:SYRE
Biotechnology 84.34%
3SBio Inc
F:83B
Biotechnology 10.64%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
Biotechnology 0.02%
Novavax Inc
NASDAQ:NVAX
Biotechnology 53.87%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Hemostemix Inc (2017–2018)

The table below shows the annual Asset Resilience Ratio data for Hemostemix Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2018-12-31 0.00% CA$0.00
≈ $0.00
CA$1.66 Million
≈ $1.20 Million
--
2017-12-31 23.66% CA$1.25 Million
≈ $907.60K
CA$5.30 Million
≈ $3.84 Million
--
pp = percentage points

About Hemostemix Inc

V:HEM Canada Biotechnology
Market Cap
$6.82 Million
CA$9.42 Million CAD
Market Cap Rank
#27925 Global
#1220 in Canada
Share Price
CA$0.05
Change (1 day)
-9.09%
52-Week Range
CA$0.05 - CA$0.15
All Time High
CA$13.40
About

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopat… Read more